This Fall PotNetwork Holdings, Inc. Will Launch The “PotNetwork Magazine” Giving You an Insider’s Take on The Cannabis Industry
PotNetwork Holdings’ “PotNetwork News” (www.potnetwork.com), the cannabis industry’s top outlet for financial, political, and industry news is set to launch the first edition of their all-new print magazine. PotNetwork Magazine gives the crack PotNetwork editorial team an opportunity to provide an unparalleled analysis of the untold stories of the cannabis space, while still channeling the unbiased, hard hitting style that has made PotNetwork.com such a sensation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005318/en/
PotNetwork Magazine (Photo: Business Wire)
PotNetwork Magazine will explore every sector of the cannabis industry from ancillary companies all the way up to growers who directly touch the plant. It will become an indispensable resource for industry leaders and budding entrepreneurs alike. The magazine will include detailed analysis of topics including hemp products, consumption devices, investing & finance, breaking technology and much more.
“There’s so many stories that don’t get told when you’re keeping up with the day’s events,” said Kevin Hagen, CEO of PotNetwork Holdings, the parent company of PotNetwork Media Group, Inc. “With PotNetwork Magazine, we can tell those stories. Whether it’s a vape shop owner or a CEO of a billion-dollar licensed producer, now we can take the time to find out what makes the cannabis industry tick.” He added, “For the parent company, publishing a magazine is exciting since it expands and underscores our position as an informational authority to the cannabis industry and our mission as a media company. Simultaneously we remain focused on the rapid growth of our product portfolio of hemp-derived CBD products from our other subsidiary, Diamond CBD, Inc. (www.DiamondCBD.com)”
For its inaugural issue, set to come out in Q4 of 2018, PotNetwork Magazine has an exciting slate of stories planned. There will be a close look at the ag-tech sector with a feature on home-grown marijuana, along with an expansive review of the new marriage between the beverage industry and cannabis. PotNetwork Magazine also plans a few in-depth interviews that readers won’t want to miss, including their feature article with George Scorsis, the CEO of Liberty Health Sciences, one of the fastest growing medical cannabis companies on the market today.
“With PotNetwork News we tell readers what’s going on every day in the cannabis industry,” said Brandon A. Dorfman, Editor-in-Chief of PotNetwork. “With PotNetwork Magazine we can give our readers so much more, telling them not only what’s going on now, but what happened before and what will happen in the future. It’s really an exciting time to be a part of things around here.”
Ample advertising space and a highly engaged readership from across the industry present a unique opportunity for businesses in the industry to connect. With widespread circulation among all levels of the industry, from producer to consumer, expected cannabis businesses will be able to tap into a unique demographic unavailable anywhere else. For more information on how to take advantage of this unique advertising opportunity please contact advertising@potnetwork.com.
About “PotNetwork”
PotNetwork News is the cannabis sector’s number one news and information site, covering the latest in financial, political, and industry news. Looking at the cannabis industry from the outside in, PotNetwork diligently reports on everything from recreational cannabis to medical marijuana, the CBD industry, and more. PotNetwork News is published by PotNetwork Media Group, Inc., a subsidiary of PotNetwork Holdings, Inc. and can be found on the web at www.potnetwork.com.
About PotNetwork Holdings, Inc.
PotNetwork Holdings, Inc. (OTC Pink: POTN) is a publicly traded company that acts as a holding company for its principal subsidiaries, PotNetwork Media Group, Inc., the publisher of PotNetwork News and PotNetwork Magazine, and First Capital Venture Co., the owner of Diamond CBD, Inc., the maker of Diamond CBD products. For more information, please visit its website at www.potnetworkholding.com.
About Diamond CBD, Inc.
Diamond CBD focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD’s team consists of hemp industry pioneers and natural product experts, chemists, doctors and scientists, dedicated to producing the finest and purest cannabidiol (CBD) oils. The result is a robust selection considered among the most powerful natural CBD oils, tinctures, edibles, and vape liquids found anywhere. For more information, please visit its website at www.DiamondCBD.com.
Safe Harbor: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005318/en/
Contact information
PotNetwork Holdings, Inc.
Marisol Elwell, 1-800-915-3060
investor@PotNetworkHolding.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom